Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

Buse, 2011 - exenatide vs placebo add on insulin

Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)

DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin

DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine

Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET

DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone

Goodman, 2009 - vildagliptin vs placebo (add on to metformin)

HOME, 2009 - metformin vs placebo

LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET

Nauck (Sulf vs pbo), 2009 - vs placebo

9607, 2009 - exenatide vs placebo add on MET+/-SU

Li, 2009 - nateglinide vs repaglinide

LEAD-2 (vs MET), 2009 - liraglutide vs metformin

Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)

LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride

Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )

COSMIC, 2009 - vs

LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET

DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)

RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs

Nauck, 2009 - alogliptin vs placebo (add on to metformin)

Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog

Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide

Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)

Moretto, 2008 - exenatide vs placebo



See also:

  • All test diabète clinical trials
  • All diabetes clinical trials
  • All type 2 diabetes - sanofi clinical trials
  • All clinical trials of insulin secretagogues peptides (incretins)
  • All clinical trials of liraglutide
    		•  

    LEAD-4 study, 0

    [NCT00333151] download pdf: liraglutide | insulin secretagogues peptides (incretins) for diabetes

    Treatments

    Studied treatment Liraglutide 1.2–1.8 mg daily
    Control treatment Placebo on-top of thiazolidinediones+metformin
    Concomittant treatment TZD+/-metformin

    Patients

    Baseline characteristics
    Age (year) 55  
    Duration of diabetes (year) 9.2 y 
    HbA1c (%) 8.5 
    BMI 33.5 
    Add-on to TZD+/-Met 

    Method and design

    Randomized effectives 356 / 177 (studied vs. control)
    Blinding not reported
    Follow-up duration 26 weeks


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    severe hypoglycemia

    0 / 356
         0 / 177
         classic 0,50 [0,00;126,72]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    severe hypoglycemia 0 / 356 (0,1%) 0 / 177 (0,3%) 0,50 [0,01;24,95] 12053
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:
  • 12053: Monami M, Marchionni N, Mannucci EGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.Eur J Endocrinol 2009;160:909-17

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.

    Meta-analysis of all similar trials:

    antidiabetic drugs in test diabète for type 2 daibetes (NIDD)

    insulin secretagogues peptides (incretins) in diabetes for all type of patients

    insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients



    Reference(s)

    Trials register # NCT00333151
    • Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, , . Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).. Diabetes Care 2009;32:1224-30. - 10.2337/dc08-2124
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend